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Metabolic engineering with systems biology tools
to optimize production of prokaryotic secondary
metabolites†
Hyun Uk Kim,*ab Pep Charusanti,b Sang Yup Leeab and Tilmann Weber*b
Covering: 2012 to 2016
Metabolic engineering using systems biology tools is increasingly applied to overproduce secondary
metabolites for their potential industrial production. In this Highlight, recent relevant metabolic
engineering studies are analyzed with emphasis on host selection and engineering approaches for the
optimal production of various prokaryotic secondary metabolites: native versus heterologous hosts (e.g.,
Escherichia coli) and rational versus random approaches. This comparative analysis is followed by
discussions on systems biology tools deployed in optimizing the production of secondary metabolites.
The potential contributions of additional systems biology tools are also discussed in the context of
current challenges encountered during optimization of secondary metabolite production.
1 Introduction
Microorganisms serve as an important source of secondary
metabolites that have various medicinal and industrial uses.1
According to Newman and Cragg,2 who investigated the source
of new drugs within a 30 year period from 1981–2010, 69% and
75% of newly introduced anti-infective and anti-cancer drugs,
respectively, were natural products or their derivatives; this
indicates the importance of natural products and the huge
potential for the discovery of novel drug leads.3,4 Bacteria of the
family Actinomycetaceae, in particular, are prolic producers of
secondary metabolites. These bacteria are the biological source
of many drugs that, for example, are used in the treatment of
infections (e.g., streptomycin and erythromycin), as immuno-
suppressants (e.g., rapamycin), and as anthelmintics (e.g., iver-
mectins). In addition, many other genera, such as myxobacteria,
bacilli, andmanymarine bacteria, have the capability to produce
complex bioactive secondary metabolites. Bacteria, mainly of the
Streptomyces genus, appear to be the fourth largest source of
FDA-approved drugs at 16%overall.5 This amount is greater than
the number of drugs derived from fungi (12% overall).
In most described cases, biosynthetic pathways for secondary
metabolites are organized as biosynthetic gene clusters (BGCs),
which means that genes encoding core biosynthetic enzymes
(e.g., polyketide synthase and non-ribosomal peptide synthe-
tase), genes encoding tailoring enzymes, genes encoding for
specic precursor biosynthesis pathways, cluster-situated regu-
lators and oen genes encoding transporters or resistance
factors are physically clustered on the chromosome. Thus, all
required genes for the production of a secondary metabolite are
encoded within such BGCs (Fig. 1).6
Recently, the discipline of metabolic engineering has
increasingly been applied to the secondary metabolite studies
to help boost commercial production of target molecules.6,7 The
general objective of metabolic engineering is to overproduce
chemicals that are valuable to mankind from microbial or
mammalian cells, and was rst coined in the eld of
biochemical engineering.8 By its denition, this discipline
attempts to systematically understand and engineer a cell's
metabolic network at a systems level.9–11 Although conventional
metabolic engineering takes a rational approach, a random
approach such as adaptive laboratory evolution is also consid-
ered to be a part of metabolic engineering in recent years.12
Moreover, due to advances in systems and synthetic biology,
a suite of high-throughput molecular and computational tools
are increasingly deployed in the practice of metabolic engi-
neering such that the eld is now oen called ‘systems meta-
bolic engineering’.11 Systems metabolic engineering has been
rigorously applied to platform production strains such as
Escherichia coli and Saccharomyces cerevisiae for the production
of various chemicals, biofuels and biopolymers.13 In this
Highlight, both ‘metabolic engineering’ and ‘systems metabolic
engineering’ are used interchangeably.
Traditionally, the metabolic engineering and secondary
metabolite communities have focused on diﬀerent goals. In
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conventional metabolic engineering, quantitative values such
as titer, yield and productivity for a target biochemical from
a production host are more heavily emphasized.11,14 These
quantitative values constitute a production host's performance
metrics in strain development. In contrast, the secondary
metabolite studies seem to have focused more on the discovery
of novel and diverse chemical structures and any possible
bioactivity they might have. This focus stems partly from the
unique biochemical logic of secondary metabolite BGCs, whose
manipulation can give rise to diverse chemical structures as
output. Manipulation of BGCs, including inactivation or
exchange of domains in polyketide synthase and non-ribosomal
peptide synthetase, engineering of a domain active site and
tailoring enzymes, and shuﬄing of modules, can all lead to the
production of secondary metabolites with novel structures, and
has been a classical topic in the secondary metabolite
community.6,15 With this background in mind, it has become
important to view the production of secondarymetabolites from
the metabolic engineer's perspective. A motivation is that once
a structurally novel molecule is suﬃciently determined to have
commercial value, its production titer and yield need to be
enhanced in order to implement larger-scale experiments,
including (pre)clinical trials, and ultimately industrial produc-
tion (Fig. 1).7 Such production optimization has recently
become even more important because some secondary metab-
olites and their precursors have been identied by the meta-
bolic engineering community to be important sources of
industrial chemicals and biofuels that have conventionally been
produced from petrochemical processes.16–18
To this end, this Highlight discusses recent studies on the
metabolic optimization of native producers and other heterol-
ogous hosts for enhanced production of secondary metabolites.
In particular, we focus on prokaryotic secondary metabolites
because of their high contribution to currently marketed drugs,5
and their potential as a source of industrial chemicals and
fuels.16–18 First, we analyze recent trends in metabolic
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engineering conducted to enhance the production of various
secondary metabolites with emphasis on host selection and
diﬀerent types of engineering approaches used (i.e., rational,
random or combined). This analysis is based on a survey of
relevant studies reported since 2012. Second, we review various
systems biology tools that have been applied to microbial hosts
for the enhanced production of secondary metabolites. These
tools are discussed in the context of current challenges
encountered during the production of secondary metabolites.
2 Recent trends in metabolic
engineering for production of
secondary metabolites
2.1 Diﬀerent considerations for host selection when
producing primary and secondary metabolites
Selection of a production host determines the suite of tools to
be deployed for strain optimization, and therefore is a very
important starting point of metabolic engineering.11 While
variables considered for selecting microbial host to produce
primary metabolites are also applicable to secondary metabolite
production studies, diﬀerent priorities appear to exist when
optimizing the production of primary and secondary metabo-
lites as target bioproducts (Fig. 2). Representative primary
metabolites considered for bioproducts include those bio-
synthesized in central carbon metabolism (e.g., ethanol, lactic
acid and succinic acid), amino acids and recently fatty acids.
Diﬀerent priorities are largely caused by stark diﬀerences in the
biochemistry of primary and secondary metabolites. Primary
metabolites, in particular fermentation products and their
derivatives, are oen produced in high titers at the scale of
grams per liter, whereas secondary metabolites are secreted at
much lower levels, typically at the scale of micrograms or
milligrams per liter. However, production of secondary metab-
olites can also reach the scale of grams per liter upon metabolic
engineering.19,20 For this reason, units of titer, yield and
productivity for production of primary metabolites are usually
dened to be ‘g L1’, ‘g g1’ and ‘g L1 h1’, respectively, but can
be varied for secondary metabolites.
A key consideration for host selection in conventional
metabolic engineering (e.g., overproducing primary metabolites
using model organisms) has been whether it is possible to
maintain both high growth and production rates using dened
minimal or industrial media, which are directly linked to the
operation cost of a microbial bioprocess;21 cheaper nutrient
utilization is always more favored from a bioprocess perspec-
tive. The availability of biosynthetic reactions for the production
of a target biochemical is also an important criterion for host
selection, but it has been somewhat overcome with state-of-the-
art synthetic biology tools for model organisms.22,23 Industrially
or medicinally valuable compounds, such as 1,4-butanediol and
opioid compounds, have been successfully produced from
engineered heterologous production hosts E. coli24 and S. cer-
evisiae,25 respectively, by constructing heterologous biosynthetic
pathways.
Fig. 1 Three major stages that lead to the optimized production of secondary metabolites from secondary metabolite-producing microor-
ganism. In the context of rational engineering, each indicated component (e.g., metabolite precursors, regulations, medium design, etc.) can be
engineering targets. Five colored circles indicate diﬀerent systems biology tools discussed, and are positioned near each component name
where most applicable. Be noted, however, that applications of the shown systems biology tools are not necessarily conﬁned to the indicated
components. The word “Signals” in the ﬁgure can be any environmental conditions (e.g., aeration, co-culturing with another microorganism and
temperature) or chemical elicitors (e.g., antibiotics at sub-lethal concentration and quorum sensing-dependent signaling molecules) that can
inﬂuence the expression of secondary metabolite biosynthetic gene clusters.75
This journal is © The Royal Society of Chemistry 2016 Nat. Prod. Rep., 2016, 33, 933–941 | 935
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Meanwhile, studies on the production of secondary metab-
olites using native hosts (e.g., actinomycetes) or heterologous
hosts have additional considerations in addition to those
already considered for the production of primary metabolites
oen using model organisms (Fig. 2). Culturability of a native
production host can be a major issue because some secondary
metabolite-producing microorganisms are unculturable, and
do not grow fast enough or with suﬃcient reproducibility
despite possession of secondary metabolite BGCs of interest.26
If a target BGC never gets expressed in a native host, a heterol-
ogous host should be considered. Doing so introduces the
challenge of capturing or cloning the BGC, which can be 100 kb
in length or more, and optimally expressing genes within the
BGC. Advanced synthetic biological tools greatly aid this
process.6,27 Finally, because general gene manipulation tools,
such as knockout and overexpression of genes, have actively
been applied to secondary metabolite-producing microorgan-
isms as manifested in next section (Table S1†), they no longer
appear to be a limiting factor for host selection when producing
secondary metabolites. In the same line, state-of-the-art
synthetic biology tools mostly developed with model organisms
(e.g., E. coli) are increasingly available to secondary metabolite
producers.28,29
2.2 Recent trends in host selection and engineering
approaches: native versus heterologous hosts and rational
versus random approaches
In order to gain insights on recent trends in host selection and
engineering approaches deployed to optimize the production of
secondary metabolites, we conducted a literature survey on
relevant studies reported since 2012 (Table S1†). Our survey
reveals that production studies using native producers
outnumber those using heterologous hosts (Fig. 3A). For native
producers, diverse hosts such as Saccharopolyspora spinosa,
Streptomyces bingchenggensis, Streptomyces chattanoogensis and
Streptomyces roseosporus, have actively been subjected to
production optimization of their native secondary metabolites.
These hosts are not necessarily model actinomycetal species.
Meanwhile, heterologous production hosts were not conned to
actinomycetes such as S. coelicolor30 and Streptomyces ven-
ezuelae31 because biologically distant and/or model organisms
such as E. coli,32 Bacillus subtilis33 andMyxococcus xanthus34were
also considered (Table S1†). Production performances of these
heterologous hosts oen appeared to be worse or at least not
better than native producers, and the secondary metabolite
production studies currently seem to favor the use of native
producers.35 However, a potential advantage of using a model
organism as a heterologous production host (e.g., E. coli) would
be better access to the state-of-the-art synthetic biology
approach in comparison with native secondary metabolite
producers. In a recent study using E. coli for the deoxyviolacein
production,36 deoxyviolacein biosynthetic pathway was divided
into two modules with L-tryptophan as a key intermediate, and
heterologous expression of each module was independently
optimized. In this optimization procedure, a molecular
biosensor was newly developed and used to detect the intra-
cellular pool of L-tryptophan along with uorescence-activated
cell sorting. This approach led to a titer of 1.92 g L1.
Also, among the metabolic engineering studies examined
(Table S1†), rational approaches were more frequently deployed
than conventionally-used random (e.g., ribosome engineering
using antibiotics at sub-lethal concentrations) and combined
approaches (Fig. 3B).37,38 Examples of the rational approaches
used to improve the production of secondary metabolites
include the enhanced supply of intracellular precursors39,40 and
the overexpression of positive regulators41 and/or removal of
competing pathways leading to other byproducts.42 These
rational approaches also employed systems biology tools such
Fig. 2 Flowchart of systems metabolic engineering considered for
secondary metabolite production. Steps in red are speciﬁc to the
secondary metabolite production, and can be considered altogether
as examining the candidate host strain's native production capacity for
a target bioproduct in the case of primary metabolite production. BAC
and BGC stand for bacterial artiﬁcial chromosome and biosynthetic
gene cluster, respectively. The step “Systemsmetabolic engineering” is
also applicable to the primary metabolite production, and further
details can be found elsewhere.11
936 | Nat. Prod. Rep., 2016, 33, 933–941 This journal is © The Royal Society of Chemistry 2016
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as statistical medium optimization43 and genome-scale meta-
bolic modeling44,45 (see next section). Rational approaches are
expected to remain dominant due to recent releases of precise
gene manipulation tools specically developed for actinomy-
cetes, for instance CRISPR-Cas9.28,29 In one recent metabolic
engineering study, Streptomyces pristinaespiralis was systemati-
cally engineered to improve its production of pristinamycin II.19
The pristinamycin II biosynthetic gene cluster was duplicated
using a modied Gibson assembly method for its over-
expression. Also, the combined eﬀects of knocking out
repressor genes and overexpressing activator genes were
examined. Finally, macroreticular resin was added to the
medium in order to facilitate separation of pristinamycin from
the medium, thereby reducing feedback inhibition by pristi-
namycin. Final engineered strain produced 1.16 g L1 of pris-
tinamycin II from 5 L bioreactor, corresponding to 5.26-fold
increase in titer, compared to the parental strain.
Although it is extremely diﬃcult to predict changes in the
relative frequency of using native and heterologous hosts for the
optimal production of secondary metabolites in coming years,
lines of evidence collected herein suggest that native producers
can serve as competitive hosts. This conclusion is also sup-
ported by large fold increases in production titer (or yield) of
secondary metabolites from native producers upon their engi-
neering (Table S1†). Technical aspects of molecular technolo-
gies used for the enhanced production of secondary metabolites
are extensively discussed elsewhere.6,15,35
3 Systems biology tools to optimize
production of secondary metabolites
As just mentioned, many metabolic engineering eﬀorts to boost
the production of secondary metabolite are centered on engi-
neering native producers. In this case, systems biology tools
tend to be more important than synthetic biology tools initially
because one needs to gain insights into the fundamental
biochemistry of native producers before actually engineering
them. Therefore, we next discuss systems biology tools that have
been used in the study on optimization of secondary metabolite
production (Table S1†). We also discuss additional systems
tools that can be further considered to overcome current chal-
lenges associated with secondary metabolite production.
3.1 Genome-scale metabolic models
Genome-scale metabolic modeling has become a popular
rational approach to enhance the production of secondary
metabolites.46,47 Genome-scale metabolic models continue to be
an important tool in systems biology by predicting global
metabolic ux distributions under given genetic and environ-
mental conditions. A genome-scale metabolic model is a large-
scale stoichiometric model that describes all the metabolic
pathways experimentally and/or theoretically characterized
through stoichiometric coeﬃcients and mass balances of
participating metabolites, and is simulated using numerical
optimization.9 This modeling approach takes an assumption of
pseudo-steady state, which can be best applied to simulating
primary metabolism in an exponential growth phase.9 Meta-
bolic questions that can be best addressed with genome-scale
metabolic models include, but are not limited to, prediction of
the most eﬃcient pathway that leads to the maximal production
yield of a target bioproduct, and optimization of precursor
supply and intracellular redox balances, typically through
prediction of the eﬀects of gene knockouts and over-
expressions.48,49Due to its ease of implementation and relatively
high predictive power, this modeling approach has contributed
to a diverse array of applications,11,50 for example prediction of
gene manipulation targets in metabolic engineering for
enhanced biochemical production,21 and prediction of drug
targets in microbial pathogens51 and cancers (e.g., hepatocel-
lular carcinoma).52 Genome-scale metabolic models can be
relatively easily created using the genome sequence of an
organism.53,54 Several soware programs have been introduced
to automate a large part of the metabolic modeling procedure,
which enable the rapid reconstruction of dra genome-scale
metabolic models of multiple species.55,56
In recent years, genome-scale metabolic models have
been manually constructed for Amycolatopsis balhimycina,57
Fig. 3 Number of reported studies aimed at enhancing the production of prokaryotic secondary metabolites using (A) diﬀerent types of
production hosts and (B) engineering approaches (i.e., rational, random or combined). Summaries of each study are available in Table S1.† Search
words in PubMed were: production[tiab] AND engineering[tiab] AND (secondary metabolites OR polyketides OR nonribosomal peptides OR
lactam OR glycopeptide OR macrolide) NOT plant AND 2012:2016[dp]; (secondary metabolite[tiab] OR natural product[tiab] OR actinomycetes
[tiab] OR streptomyces[tiab]) AND (design[tiab] OR engineering[tiab]) AND 2012:2016[dp].
This journal is © The Royal Society of Chemistry 2016 Nat. Prod. Rep., 2016, 33, 933–941 | 937
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S. coelicolor,45 Saccharopolyspora erythraea,44 S. spinosa,58 Strep-
tomyces lividans59 and Streptomyces tsukubaensis60 (Table S1†).
Genome-scale metabolic models of S. erythraea and S. spinosa
were used to identify the eﬀects of supplementing amino acids
in media on production yield,44,58 while those of A. balhimycina,
S. coelicolor and S. tsukubaensis were used to identify gene
manipulation targets to enhance target production.45,60,61 In
these metabolic models, only experimentally known secondary
metabolite biosynthetic pathways were considered. For
example, separate biosynthetic pathways for actinorhodin,
undecylprodigiosin, calcium-dependent antibiotic, ectoine, and
germicidin were included in the latest version of the S. coelicolor
metabolic model,45 while the S. erythraea metabolic model
describes biosynthetic pathways for erythromycin, 2-methyl-
isoborneol, rhamnosylaviolin, and erythrochelin.44
Now that many BGCs can be eﬀectively detected using so-
ware programs (e.g., antiSMASH53), incorporating their corre-
sponding biosynthetic reactions into metabolic models
becomes an important task. The biosynthetic reactions for
several clusters have been characterized, but the majority have
not. More complete information on secondary metabolite
biosynthetic reactions would help to evaluate systematically the
production capacity of secondary metabolite producers of
interest using metabolic models. Zakrzewski et al. demon-
strated a proof-of-concept study relevant to this issue by auto-
matically generating genome-scale metabolic models of 38
actinobacteria, and predicting theoretical production capacity
of each strain for 15 heterologously expressed secondary
metabolites. The prediction outcomes showed that large
genomic sizes do not necessarily lead to optimal production.56
Interestingly, in addition to the studies summarized in Table
S1,† D'Huys et al. investigated the eﬀects of growing S. lividans
under complex media using its genome-scale metabolic model.
The metabolic studies revealed that nutritionally rich media do
not necessarily lead to maximal biomass formation.59 Although
this study was aimed at heterologous production of proteins, it
is noteworthy because actinomycetes are almost always culti-
vated in complex media, and elucidating the eﬀects of complex
media on the production of secondary metabolites will be an
invaluable resource in the context of bioprocess optimization.
3.2 Medium design using statistical optimization
Although genome-scale metabolic modeling can partly address
the problem of media optimization as mentioned above, this
area oen requires more thorough independent analyses.
Media components heavily inuence the production perfor-
mance of microbial hosts because the cells use diﬀerent meta-
bolic pathways depending on the availability of diﬀerent
nutrients in the media. A challenge here is that the design of
optimal media for the best possible production performance is
oen complicated by a large possible number of combinations
of nutrients. For this reason, a ‘design-of-experiments (DOE)’
approach has oen been applied to media optimization in
bioprocess engineering for the enhanced production of various
bioproducts, including secondary metabolites.62 Frequently
deployed methods have been statistical optimization involving
Plackett–Burman design and response surface methodology,
leading to identication of key medium components along with
their optimal concentrations. Recently, this statistical optimi-
zation approach has been applied to the production of dapto-
mycin from a S. roseosporus mutant strain,63 neomycin from
Streptomyces fradiae,64 nosiheptide from Streptomyces actuosus,65
and pikromycin from S. venezuelae.43 In all these studies,
minerals and/or carbon sources that most aﬀected the
secondary metabolite production were selected, and their
optimal concentrations were determined using the Plackett–
Burman design and response surface methodology. The DOE
approach will continue to play an important role in optimizing
multiple bioprocess variables, including microbial cultivation
media.
3.3 13C-Metabolic ux analysis
A similar approach to the aforementioned genome-scale meta-
bolic modeling is 13C-metabolic ux analysis, which also uses
information on mass balance of metabolites with their stoi-
chiometric coeﬃcients.9 However, the two diﬀer in that
13C-metabolic ux analysis uses 13C-labelling data from isotopic
labelling experiments in addition to a stoichiometric metabolic
network model in order to estimate in vivo metabolic uxes
under a given condition. Despite its precise measurement of in
vivo ux values, 13C-metabolic ux analysis has not been
frequently deployed to analyze metabolism of secondary
metabolite-producing microorganisms in the past when
compared to model organisms.46,66 Recently, Coze et al. inves-
tigated diﬀerences in metabolic ux distributions of an acti-
norhodin-producing S. coelicolor wild-type and its mutant, in
which its native four BGCs were removed.67 13C-Metabolic ux
analysis revealed a few insights, including amore active pentose
phosphate pathway in the mutant, and a competition for
common precursors such as acetyl-CoA between primary and
secondary metabolism. Although this study was not intended
for production optimization, the 13C-metabolic ux analysis
used in this study could be useful in analyzing the metabolic
status of engineered strains towards enhanced production.
Finally, use of dynamic 13C-metabolic ux analysis should be
useful in analyzing metabolic status during the secondary
metabolite production phase that is in non-steady state.68
Because many complex regulations take place during the
secondary metabolite production, conventional 13C-metabolic
ux analysis based on the pseudo-steady state assumption, in
the strict sense, is not an ideal approach to analyze this specic
metabolic status. Also, dynamic 13C-metabolic ux analysis can
be more advantageous for the analysis of microbial metabolism
in fed-batch fermentations because this fermentation mode has
very dynamic cultivation conditions. Fed-batch fermentations
are predominantly conducted in industry.
3.4 A challenge of identifying metabolic and regulatory gene
manipulation targets and further systems approaches to be
considered
Identifying metabolic and/or regulatory genes responsible for
the enhanced production of secondary metabolites stands as an
938 | Nat. Prod. Rep., 2016, 33, 933–941 This journal is © The Royal Society of Chemistry 2016
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important challenge. We expect that additional systems biology
tools available in the metabolic engineering community, which
have not been applied to the secondary metabolite production
yet, will help to meet this challenge.
First, the aforementioned genome-scale metabolic model
contains information about the reactions that lead to secondary
metabolite biosynthesis, but it does not contain any regulatory
information. Probabilistic modeling approach is likely to be
a good option to model regulation associated with secondary
metabolite biosynthesis. As a relevant recent example, a regu-
latory network describing relationships between genes encod-
ing transcription factors and their target metabolic genes was
modeled by calculating conditional probabilities for Mycobac-
terium tuberculosis.69 In this modeling approach, conditional
probabilities are used to describe relationship between tran-
scription factors and their target metabolic genes; they reveal
the probability that a metabolic gene gets expressed or inacti-
vated, depending on the expression status of a transcription
factor. This probabilistic information is used to calculate more
accurate metabolic ux values using the genome-scale meta-
bolic model of M. tuberculosis. A similar integrative modeling
approach can be considered to identify regulatory genes that
can boost the expression of metabolic genes related to the
biosynthesis of a target secondary metabolite.
The above probabilistic regulatory modeling approach in
turn requires a large transcriptome dataset to bestow greater
reliability on the calculated conditional probabilities for meta-
bolic genes and transcription factors. Of particular importance
is that the large transcriptome (or other omics) dataset needs to
be obtained from as many diﬀerent environmental and/or
genetic conditions as possible in order to accurately determine
the conditional probabilities that describe relationships
between genes. Massive transcriptome analyses have been
conducted for S. coelicolor under multiple conditions in the
past, for example, elucidating: nutritional stress response of an
antibiotic regulator AfsS,70 a genome-wide regulatory network,71
genome-wide gene expression changes during a metabolic
switch from exponential to stationary antibiotic production
phase,72 and sigma factor-regulated genes in germination.73
Despite several massive transcriptome analyses conducted on
actinomycetes (or heterologous model hosts), they have barely
been deployed to enhance the production of secondary metab-
olites. Generation of massive omics data in the context of
secondary metabolite production should be very important
resources for optimizing the whole bioprocess.
3.5 A starting point of systems biology and metabolic
engineering studies for secondary metabolites: the Secondary
Metabolite Bioinformatics Portal
BGCs of secondary metabolites are a very complex system, and
therefore optimization of secondary metabolite production
requires relevant insights before actual metabolic engineering
for production optimization begins. This step can be particu-
larly challenging for metabolic engineers who are not familiar
with the biology of actinomycetes. To this end, we recently
released the Secondary Metabolite Bioinformatics Portal
(SMBP) available at http://secondarymetabolites.org/, which
provides a full list of databases and tools dedicated to
secondary metabolite bioinformatics, along with their
descriptions and URLs.54 This portal provides a concise
gateway to various bioinformatic resources and tools that can
facilitate metabolic engineering of actinomycetes and heterol-
ogous model hosts, including databases of secondary metab-
olites and BGC mining tools (e.g., antiSMASH). There are also
other soware tools with more generic applications, for
example CRISPy-web, an application that supports the design
of guideRNAs (sgRNAs) for CRISPR-Cas9 mediated genetic
manipulation of microorganisms.74
3.6 Perspectives on the direction of secondary metabolite
production studies
It should be noted that systems biology tools used in metabolic
engineering are complementary to tools and strategies that have
been uniquely developed and used for secondary metabolite
studies. An obvious reason is that the production of secondary
metabolites needs unique considerations that are distinct from
those of the primary metabolite production (Fig. 2). For the
optimal production and potential commercialization of
secondary metabolites, following considerations can be useful.
First, processes of systems metabolic engineering need to be
taken into account at an early phase of the secondary metabolite
production study (e.g., genomemining and host selection). This
will enable decision-makings not only from a pure biochemistry
perspective, but also from an engineering perspective, leading
to an integral pipeline from novel secondary metabolite iden-
tication to its optimal production. Second, metabolic engi-
neers also need to have a better understanding of the working
mechanism of secondary metabolite BGCs. This will facilitate
introduction of state-of-the-art tools to secondary metabolite
producers, which were initially developed for model organisms.
With recent eﬀorts, more relevant achievements are awaiting to
be realized.17,28,29,36
4 Conclusions
As the discipline of metabolic engineering has expanded into
the realm of prokaryotic secondary metabolites, this Highlight
aimed to review the current status of metabolic engineering for
secondary metabolite production and the relevant systems
biology tools used. While our analysis manifested the progress
made for the optimal production of secondary metabolites, it
also clearly pinpointed room for further development. In
particular, state-of-the-art systems biology tools established for
the metabolic engineering community, including integrative
metabolic and regulatory modeling, (dynamic) 13C-metabolic
ux analysis and omics data generation, have not been fully
deployed in the production optimization of secondary metab-
olites. Upon successful implementation of such tools, more
diverse secondary metabolites will be considered for industrial
production and commercialization in both medicinal and
chemical industries.
This journal is © The Royal Society of Chemistry 2016 Nat. Prod. Rep., 2016, 33, 933–941 | 939
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